Cargando…

Mutations Status of Chemokine Signaling Pathway Predict Prognosis of Immune Checkpoint Inhibitors in Colon Adenocarcinoma

In recent years, tumor immunotherapy has become an important treatment program and popular research focus. However, the use of immune checkpoint inhibitors (ICI) in the treatment of colorectal cancer still has limitations due to the current markers only being able to predict the prognosis of a small...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Anqi, Xu, Wentao, Luo, Peng, Zhang, Jian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8551610/ https://www.ncbi.nlm.nih.gov/pubmed/34721019 http://dx.doi.org/10.3389/fphar.2021.721181

Ejemplares similares

Prognosis of Lung Adenocarcinoma Patients With NTRK3 Mutations to Immune Checkpoint Inhibitors
por: Niu, Yuchun, et al.
Publicado: (2020)

Catenin Alpha-2 Mutation Changes the Immune Microenvironment in Lung Adenocarcinoma Patients Receiving Immune Checkpoint Inhibitors
por: Wen, Yang, et al.
Publicado: (2021)

Mutations Status of NOTCH Signaling Pathway Predict Prognosis of Immune Checkpoint Inhibitors in Colorectal Cancer
por: Lin, Anqi, et al.
Publicado: (2023)

B Cell Receptor Signaling Pathway Mutation as Prognosis Predictor of Immune Checkpoint Inhibitors in Lung Adenocarcinoma by Bioinformatic Analysis
por: Lin, Anqi, et al.
Publicado: (2022)

Comprehensive Analysis Identifies PI3K/Akt Pathway Alternations as an Immune-Related Prognostic Biomarker in Colon Adenocarcinoma Patients Receiving Immune Checkpoint Inhibitor Treatment
por: Lin, Anqi, et al.
Publicado: (2022)

Cardiotoxicity associated with immune checkpoint inhibitors: Current status and future challenges
por: Gan, Lu, et al.
Publicado: (2022)

Activation of the chemokine receptor 3 pathway leads to a better response to immune checkpoint inhibitors in patients with metastatic urothelial carcinoma
por: Feng, Wenqin, et al.
Publicado: (2022)

Risk Factors, Incidence, and Prognosis of Thromboembolism in Cancer Patients Treated With Immune Checkpoint Inhibitors
por: Zou, Xue-lin, et al.
Publicado: (2021)

Neutrophil-related genes predict prognosis and response to immune checkpoint inhibitors in bladder cancer
por: Yang, Rui, et al.
Publicado: (2022)

TET1 mutations as a predictive biomarker for immune checkpoint inhibitors in colon adenocarcinoma
por: Qiu, Tianzhu, et al.
Publicado: (2022)

Axl kinase drives immune checkpoint and chemokine signalling pathways in lung adenocarcinomas
por: Tsukita, Yoko, et al.
Publicado: (2019)

Toxicity of Immune-Checkpoint Inhibitors in Hematological Malignancies
por: Hradska, Katarina, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors in Peripheral T-Cell Lymphoma
por: Chen, Xi, et al.
Publicado: (2022)

Clinical Insights Into Novel Immune Checkpoint Inhibitors
por: Lee, Jii Bum, et al.
Publicado: (2021)

Resistance to immune checkpoint inhibitors in gastric cancer
por: Liu, Kai, et al.
Publicado: (2023)

Effect of NCOR1 Mutations on Immune Microenvironment and Efficacy of Immune Checkpoint Inhibitors in Patient with Bladder Cancer
por: Lin, Anqi, et al.
Publicado: (2021)

Hyperprogressive Disease in Cancers Treated With Immune Checkpoint Inhibitors
por: Shen, Pan, et al.
Publicado: (2021)

Drug therapy for myocarditis induced by immune checkpoint inhibitors
por: Wu, Yihao, et al.
Publicado: (2023)

Immune Checkpoint Inhibitor Toxicity in Head and Neck Cancer: From Identification to Management
por: Wang, Haiyang, et al.
Publicado: (2019)

Hematological Side Effects of Immune Checkpoint Inhibitors: The Example of Immune-Related Thrombocytopenia
por: Calvo, Roser
Publicado: (2019)

How to Monitor Cardiac Complications of Immune Checkpoint Inhibitor Therapy
por: Spallarossa, Paolo, et al.
Publicado: (2020)

Neurologic Toxicity of Immune Checkpoint Inhibitors: A Review of Literature
por: Albarrán, Víctor, et al.
Publicado: (2022)

The Strategies and Mechanisms of Immune Checkpoint Inhibitors for Brain Metastases in NSCLC
por: Li, Ji, et al.
Publicado: (2022)

Immune checkpoint inhibitors in osteosarcoma: A hopeful and challenging future
por: Zhang, Zeng, et al.
Publicado: (2022)

Survival Prediction of Patients Treated With Immune Checkpoint Inhibitors via KRAS/TP53/EGFR-Single Gene Mutation
por: Liu, Shui, et al.
Publicado: (2022)

ATM Mutations Benefit Bladder Cancer Patients Treated With Immune Checkpoint Inhibitors by Acting on the Tumor Immune Microenvironment
por: Yi, Ruibin, et al.
Publicado: (2020)

Identification of Mutations Related to Cisplatin-Resistance and Prognosis of Patients With Lung Adenocarcinoma
por: Li, Rui, et al.
Publicado: (2020)

Immune-mediated hepatitis induced by immune checkpoint inhibitors: Current updates and future perspectives
por: Liu, Zherui, et al.
Publicado: (2023)

The Predictive Value of Tumor Mutation Burden on Clinical Efficacy of Immune Checkpoint Inhibitors in Melanoma: A Systematic Review and Meta-Analysis
por: Ning, Biao, et al.
Publicado: (2022)

Adverse Effects and Toxicity of Immune Checkpoint Inhibitors For Patients With Urothelial Carcinoma
por: Wang, Di, et al.
Publicado: (2021)

Potential role of gut microbes in the efficacy and toxicity of immune checkpoints inhibitors
por: Ma, Jingxin, et al.
Publicado: (2023)

Immune checkpoint inhibitor-induced aplastic anaemia: Case series and large-scale pharmacovigilance analysis
por: Guo, Qian, et al.
Publicado: (2023)

Association Between FSIP2 Mutation and an Improved Efficacy of Immune Checkpoint Inhibitors in Patients With Skin Cutaneous Melanoma
por: Ying, Haoxuan, et al.
Publicado: (2021)

Comprehensive genomics analysis of aging related gene signature to predict the prognosis and drug resistance of colon adenocarcinoma
por: Feng, Jubin, et al.
Publicado: (2023)

A Novel Integrated Metabolism-Immunity Gene Expression Model Predicts the Prognosis of Lung Adenocarcinoma Patients
por: Chen, Songming, et al.
Publicado: (2021)

Controlling Nutritional Status (CONUT) Predicts Survival in Gastric Cancer Patients With Immune Checkpoint Inhibitor (PD-1/PD-L1) Outcomes
por: Chen, Li, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors and Immune-Related Adverse Drug Reactions: Data From Italian Pharmacovigilance Database
por: Ruggiero, Rosanna, et al.
Publicado: (2020)

Loss of MHC-I antigen presentation correlated with immune checkpoint blockade tolerance in MAPK inhibitor-resistant melanoma
por: Yu, Jing, et al.
Publicado: (2022)

A Novel Immune-Prognosis Index Predicts the Benefit of Lung Adenocarcinoma Patients
por: Bai, Yuquan, et al.
Publicado: (2022)

Immune Checkpoint Inhibitor-Associated Cardiotoxicity: Current Understanding on Its Mechanism, Diagnosis and Management
por: Zhou, Yu-Wen, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_e6d7hd91v3vrgaohm3a27fpda2